eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2024
vol. 26
 
Share:
Send email
Share:
Review paper

Hodgkin’s lymphoma in adults – diagnosis and treatment

Anna Gruszczyńska
1
,
Krzysztof Kowalik
2
,
Dagmara Jabłońska
3
,
Katarzyna Hetman
4
,
Andrzej Modrzejewski
2

  1. Department of Forensic Medicine of the Pomeranian Medical University, Szczecin, Poland
  2. Clinical Department of General Surgery of the Pomeranian Medical University, Szczecin, Poland
  3. Clinical Department of Nephrology with Dialysis Station the Regional Hospital in Kielce, Kielce, Poland
  4. Department of Clinical Oncology Western Pomeranian Oncology Center in Szczecin, Szczecin, Poland
Family Medicine & Primary Care Review 2024; 26(2): 251–260
DOI: https://doi.org/10.5114/fmpcr.2024.139038
Online publish date: 2024/06/17
Article file
- 17 FM&PCR 2 24 - R - Gruszczyńska - 1368 - Hodgkin's.pdf  [0.50 MB]
Get citation
 
PlumX metrics:
 
1. Eichenauer DA, Engert A, André M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(Suppl. 3): iii70–iii75, doi: 10.1093/annonc/mdu181.
2. Kanzler H, Küppers R, Hansmann ML, et al. Hodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996; 184(4): 1495–1505, doi: 10.1084/jem.184.4.1495.
3. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001; 97(2): 496–501, doi: 10.1182/blood.v97.2.496.
4. Schwarzer R, Jundt F. Notch and NF-κB signaling pathways in the biology of classical Hodgkin lymphoma. Curr Mol Med 2011; 11(3): 236–245, doi: 10.2174/156652411795243423.
5. Diehl V, Burrichter H, Schaadt M, et al. Hodgkin’s disease cell lines: characteristics and biological activities. Haematol Blood Transfus 1983; 28: 411–417.
6. Ansell SM. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016; 91(4): 434–442, doi: 10.1002/ajh.24272.
7. Grufferman S, Cole P, Smith PG, et al. Hodgkin’s disease in siblings. N Engl J Med 1977; 296(5): 248–250.
8. Mack TM, Cozen W, Shibata DK, et al. Concordance for Hodgkin’s disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 1995; 332(7): 413–418, doi: 10.1056/NEJM199502163320701.
9. Rezaei N, ed. Hodgkin’s Lymphoma [Internet]. InTech 2012, doi: 10.5772/1469.
10. Franceschi S, Dal Maso L, La Vecchia C. Advances in the epidemiology of HIV-associated non-Hodgkin’s lymphoma and other lymphoid neoplasms. Int J Cancer 1999; 83(4): 481–485.
11. Andrieu JM, Roithmann S, Tourani JM, et al. Hodgkin’s disease during HIV1 infection: the French registry experience. French Registry of HIV-associated Tumors. Ann Oncol 1993; 4(8): 635–641.
12. DeVita VT, Lawrence TS, Rosenberg SA. Devita, Hellman & Rosenberg’s Cancer: Principles & Practice of Oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
13. Küppers R. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009: 491–496, doi: 10.1182/asheducation-2009.1.491.
14. Weiss LM, Strickler JG, Warnke RA, et al. Epstein-Barr viral DNA in tissues of Hodgkin’s disease. Am J Pathol 1987; 129(1): 86–91.
15. Alexander FE, Jarrett RF, Lawrence D, et al. Risk factors for Hodgkin’s disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer 2000; 82(5): 1117–1121.
16. Smithers DW, Lillicrap SC, Barnes A. Patterns of lymph node involvement in relation to hypotheses about the modes of spread of Hodgkin’s disease. Cancer 1974; 34: 1779–1786.
17. Musshoff K. Prognostic and therapeutic implications of staging in extranodal Hodgkin’s disease. Cancer Res 1971; 31: 1814–1827.
18. Gobbi PG, Cavalli C, Gendarini A, et al. Reevaluation of prognostic significance of symptoms in Hodgkin’s disease. Cancer 1985; 56(12): 2874–2880.
19. Picardi M, Cavaliere C, Della Pepa R, et al. PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial. Ann Hematol 2021; 100(6): 1525–1535.
20. Barrington SF, Kirkwood AA, Franceschetto A, et al. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 2016; 127(12): 1531–1538.
21. Adams HJ, Kwee TC, de Keizer B, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol 2014; 25(5): 921–927.
22. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989; 7(11): 1630–1636.
23. Mauch P, Goodman R, Hellman S. The significance of mediastinal involvement in early stage Hodgkin’s disease. Cancer 1978; 42(3): 1039–1045.
24. Bradley AJ, Carrington BM, Lawrance JA, et al. Assessment and significance of mediastinal bulk in Hodgkin’s disease: comparison between computed tomography and chest radiography. J Clin Oncol 1999; 17(8): 2493–2498.
25. American Cancer Society: Cancer Facts and Figures 2022. American Cancer Society, 2022 [cited 7.10.2022]. Available from URL: tu musi byc konkretny link.
26. Cosset JM, Henry-Amar M, Meerwaldt JH, et al. The EORTC trials for limited stage Hodgkin’s disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 1992; 28A(11): 1847–1850.
27. Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 2012; 119(3): 692–695.
28. Agostinelli C, Gallamini A, Stracqualursi L, et al. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin’s lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematol 2016; 3(10): e467–e479.
29. Gallamini A, Rossi A, Patti C, et al. Interim PET-adapted chemotherapy in advanced Hodgkin lymphoma: results of the second interim analysis of the Italian GITIL/FIL DH0607 trial. Hematol Oncol 2015; 33(Suppl. 1): 100–180.
30. Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018; 131(22): 2413–2425.
31. Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 2018; 131(13): 1456–1463.
32. Akhtari M, Milgrom SA, Pinnix CC, et al. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood 2018; 131(1): 84–94.
33. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008.
34. Stein H, Delsol G, Pileri SA. Hodgkin Lymphoma. In: Jaffe ES, Harris NL, Stein H, et al. eds. World Health Organization (WHO) Classification of Tumours: Pathology & Genetics; Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001: 237–253.
35. Weidner N, Cote RJ, Suster S, et al. Modern Surgical Pathology. Elsevier Health Sciences; 2009: 1461–1462.
36. Krzakowski M, Potemski P, Warzocha K, et al. Onkologia kliniczna. T. III. Gdańsk: Via Medica; 2015 (in Polish).
37. Kumar V, Cotran RS, Robins SL. Robins Patologia. Wrocław: Elsevier Urban & Partner; 2005: 495–498 (in Polish).
38. Mughal TI, Mughal T, Goldman J, et al. Understanding Leukemias, Lymphomas and Myelomas. 2nd ed. Boca Raton (FL): CRC Press; 2009.
39. Cheson BD, Fisher RI, Barrington SF, et al. Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin’s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32(27): 3059–3068, doi: 10.1200/JCO.2013.54.8800.
40. Jost LM, Stahel RA, ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin’s disease. Ann Oncol 2005; 16(Suppl. 1): i54–i55.
41. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998; 339(21): 1506–1514.
42. Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol 2012; 30(27): 3383–3388.
43. Eichenauer DA, Aleman BMP, Andre M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 2018; 29(Suppl. 4): ii19–ii29.
44. Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 2008; 111(6): 2977–2983.
45. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379(9828): 1791–1779.
46. Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 2015; 126(26): 2798–2804.
47. Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥ 60 years with HL. Blood 2017; 130(26): 2829–2837.
48. Evens AM, Advani RH, Helenowski IB, et al. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. J Clin Oncol 2018; 36(30): 3015–3022.
49. Herst J, Crump M, Baldassarre FG, et al. Management of Early-stage Hodgkin Lymphoma: A Practice Guideline. Clin Oncol (R Coll Radiol) 2017; 29(1): e5–e12.
50. Dühmke E, Franklin J, Pfreundschuh M, et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001; 19(11): 2905–2914.
51. Mendenhall NP, Rodrigue LL, Moore-Higgs GJ, et al. The optimal dose of radiation in Hodgkin’s disease: an analysis of clinical and treatment factors affecting in-field disease control. Int J Radiat Oncol Biol Phys 1999; 44(3): 551–561.
52. Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood 2018; 132(16): 1635–1646.
53. Canellos GP, Abramson JS, Fisher DC, et al. Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010; 28(9): 1611–1615.
54. Landgren O, Axdorph U, Fears TR, et al. A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients. Ann Oncol 2006; 17(8): 1290–1295.
55. Backstrand KH, Ng AK, Takvorian RW, et al. Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin’s disease. J Clin Oncol 2001; 19(3): 736–741.
56. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 2012; 366(5): 399–408.
57. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010; 363(7): 640–652.
58. Sasse S, Bröckelmann PJ, Goergen H, et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol 2017; 35(18): 1999–2007.
59. Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2015; 385(9976): 1418–1427.
60. Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014; 32(12): 1188–1194.
61. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 2015; 372(17): 1598–1607.
62. Fuchs M, Goergen H, Kobe C, et al. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol 2019; 37(31): 2835–2845.
63. Bröckelmann PJ, Sasse S, Engert A. Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood 2018; 131(15): 1666–1678.
64. Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127(18): 2189–2192.
65. Gunther JR, Fanale MA, Reddy JP, et al. Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy with Radiation. Int J Radiat Oncol Biol Phys 2016; 96(1): 110–118.
66. Tresckow B, von, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German hodgkin study group HD14 trial. J Clin Oncol 2012; 30(9): 907–913.
67. Fermé C, Thomas J, Brice P, et al. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d’Étude des Lymphomes de l’Adulte (GELA) H9-U intergroup randomised trial. Eur J Cancer 2017; 81: 45–55.
68. Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28(27): 4199–4206.
69. Kumar A, Casulo C, Yahalom J, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood 2016; 128(11): 1458–1464.
70. André MPE, Girinsky T, Federico M, et al. Early Positron Emission Tomography Response – Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol 2017; 35(16): 1786–1794.
71. Borchmann P, Plütschow A, Kobe C, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22(2): 223–234.
72. Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med 2018; 378(4): 331–344.
73. Straus DJ, Długosz-Danecka M, Alekseev S, et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood 2020; 135(10): 735–742.
74. Ansell SM, Radford J, Connors JM, et al. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma. N Engl J Med 2022; 387(4): 310–320.
75. Evens AM, Connors JM, Younes A, et al. Older patients (aged ≥ 60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica 2022; 107(5): 1086–1094, doi: 10.3324/haematol.2021.278438.
76. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin’s disease trial. N Engl J Med 2002; 346(18): 1417–1418.
77. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 2003; 21(4): 607–614.
78. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27(5): 805–811.
79. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 2011; 365(3): 203–312.
80. Bauer K, Skoetz N, Monsef I, et al. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011; 8: CD007941, doi: 10.1002/14651858.CD007941.pub2.
81. Chisesi T, Bellei M, Luminari S, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin’s lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol 2011; 29(32): 4227–4233.
82. Carde P, Karrasch M, Fortpied C, et al. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol 2016; 34(17): 2028–2036.
83. Mounier N, Brice P, Bologna S, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 2014; 25(8): 1622–1628.
84. Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 1994; 120(11): 903–912.
85. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 2003; 348(24): 2396–2406.
86. Fermé C, Mounier N, Casasnovas O, et al. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 2006; 107(12): 4636–4642.
87. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med 2016; 374(25): 2419–2429.
88. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol 2002; 20(1): 221–230.
89. Bonfante V, Santoro A, Viviani S, et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15(2): 528–534.
90. Garcia-Carbonero R, Paz-Ares L, Arcediano A, et al. Favorable prognosis after late relapse of Hodgkin’s disease. Cancer 1998; 83(3): 560–565.
91. Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021; 22(4): 512–524.
92. Armand P, Shipp MA, Ribrag V, et al. Programmed Death-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol 2016; 34(31): 3733–3739.
93. Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 2019; 134(14): 1144–1153.
94. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015; 372(4): 311–319.
95. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016; 17(9): 1283–1294.
96. Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol 2018; 36(14): 1428–1439.
97. Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018; 131(11): 1183–1194.
98. Gopal AK, Ramchandren R, O’Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012; 120(3): 560–568.
99. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363(19): 1812–1821.
100. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012; 30(18): 2183–2189.
101. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012; 119(26): 6379–6381.
102. Bazarbachi A, Boumendil A, Finel H, et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer 2019; 125(1): 90–98.
103. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385(9980): 1853–1862.
104. Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood 2018; 132(25): 2639–2642.
105. LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018; 132(1): 40–48.
106. O’Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1–2 trial. Lancet Oncol 2018; 19(2): 257–266.
107. Holmberg L, Maloney DG. The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. J Natl Compr Canc Netw 2011; 9(9): 1060–1071.
108. Shah GL, Moskowitz CH. Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 2018; 131(15): 1689–1697.
109. Martínez C, Gayoso J, Canals C, et al. Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J Clin Oncol 2017; 35(30): 3425–3432.
110. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359(9323): 2065–2071.
111. Rancea M, Monsef I, Tresckow B, von, et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev 2013; 6: CD009411.
112. Canellos GP, Petroni GR, Barcos M, et al. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin’s disease in relapse following MOPP. Cancer and Leukemia Group B. J Clin Oncol 1995; 13(8): 2005–2011.
113. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10(2): 210–218.
114. Böll B, Goergen H, Arndt N, et al. Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol 2013; 31(35): 4431–4437.
115. Ng AK, Li S, Neuberg D, et al. Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin’s disease. Ann Oncol 2004; 15(2): 270–275.
116. Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin’s disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 1997; 33(6): 848–853.
117. Josting A, Nogová L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005; 23(7): 1522–1529.
118. Anselmo AP, Cavalieri E, Enrici RM, et al. Hodgkin’s disease during pregnancy: diagnostic and therapeutic management. Fetal Diagn Ther 1999; 14(2): 102–105.
119. Mazonakis M, Varveris H, Fasoulaki M, et al. Radiotherapy of Hodgkin’s disease in early pregnancy: embryo dose measurements. Radiother Oncol 2003; 66(3): 333–339.
120. Greskovich JF, Macklis RM. Radiation therapy in pregnancy: risk calculation and risk minimization. Semin Oncol 2000; 27(6): 633–645.
121. Thomas PR, Biochem D, Peckham MJ. The investigation and management of Hodgkin’s disease in the pregnant patient. Cancer 1976; 38(3): 1443–1451.
122. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5(5): 283–291.
123. Jacobs C, Donaldson SS, Rosenberg SA, et al. Management of the pregnant patient with Hodgkin’s disease. Ann Intern Med 1981; 95(6): 669–675.
124. Nisce LZ, Tome MA, He S, et al. Management of coexisting Hodgkin’s disease and pregnancy. Am J Clin Oncol 1986; 9(2): 146–151.
125. Avilés A, Díaz-Maqueo JC, Talavera A, et al. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol 1991; 36(4): 243–248.
126. Harris NL. Hodgkin’s lymphomas: classification, diagnosis, and grading. Semin Hematol 1999; 36(3): 220–232.
127. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin’s lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin’s Study Group trials. J Clin Oncol 2005; 23(24): 5739–5745.
128. Moskowitz AJ. NLP Hodgkin lymphoma: can we get away with less? Blood 2020; 135(26): 2329–2330.
129. Borchmann S, Joffe E, Moskowitz CH, et al. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood 2019; 133(20): 2121–2129.
130. Eichenauer DA, Plütschow A, Fuchs M, et al. Long-Term Course of Patients with Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. J Clin Oncol 2015; 33(26): 2857–2862.
131. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 2010; 28(1): 136–141.
132. Eichenauer DA, Engert A. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood 2020; 136(26): 2987–2993.
133. Binkley MS, Rauf MS, Milgrom SA, et al. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 2020; 135(26): 2365–2374.
134. Russell KJ, Hoppe RT, Colby TV, et al. Lymphocyte predominant Hodgkin’s disease: clinical presentation and results of treatment. Radiother Oncol 1984; 1(3): 197–205.
135. Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 2011; 118(17): 4585–4590.
136. Bartlett NL. Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle. J Clin Oncol 2020; 38(7): 662–668.
137. Xing KH, Connors JM, Lai A, et al. Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood 2014; 123(23): 3567–373.
138. Fanale MA, Cheah CY, Rich A, et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood 2017; 130(4): 472–477.
139. Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 2014; 32(9): 912–918.
140. Eichenauer DA, Plütschow A, Fuchs M, et al. Long-Term Follow-Up of Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group. J Clin Oncol 2020; 38(7): 698–705.
141. Kenderian SS, Habermann TM, Macon WR, et al. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood 2016; 127(16): 1960–1966.
142. El-Galaly TC, Mylam KJ, Brown P, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica 2012; 97(6): 931–936.
143. Hartridge-Lambert SK, Schöder H, Lim RC, et al. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma. Cancer 2013; 119(6): 1203–1209.
144. Hapgood G, Zheng Y, Sehn LH, et al. Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison with the General Population in British Columbia. J Clin Oncol 2016; 34(21): 2493–2500.
145. SEER. Cancer Stat Facts: Hodgkin Lymphoma; National Cancer Institute: Bethesda, MD, USA [cited 29.09.2018]. Available from URL: https://seer.cancer.gov/statfacts/html/hodg.html.
146. Longo DL, Armitage JO. Controversies in the treatment of early-stage Hodgkin’s lymphoma. N Engl J Med 2015; 372(17): 1667–1669.
147. Aleman BM, Belt-Dusebout AW, van den, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003; 21(18): 3431–3439.
148. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a collaborative British cohort study. J Clin Oncol 2011; 29(31): 4096–4104.
149. Koontz MZ, Horning SJ, Balise R, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol 2013; 31(5): 592–598.
150. Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin’s disease. J Clin Oncol 1986; 4(6): 830–837.
151. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20(16): 3484–3494.
152. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006; 17(12): 1749–1760.
153. Chowdhry AK, McHugh C, Fung C, et al. Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma. Cancer 2015; 121(9): 1436–1445.
154. Dores GM, Curtis RE, Leeuwen FE, van, et al. Pancreatic cancer risk after treatment of Hodgkin lymphoma. Ann Oncol 2014; 25(10): 2073–2079.
155. Rigter LS, Spaander MCW, Aleman BMP, et al. High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors. Cancer 2019; 125(6): 990–999.
156. Schaapveld M, Aleman BM, Eggermond AM, van, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma. N Engl J Med 2015; 373(26): 2499–2511.
157. Lavoie JC, Connors JM, Phillips GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106(4): 1473–1478.
158. Kreissl S, Müller H, Goergen H, et al. Health-Related Quality of Life in Patients with Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. J Clin Oncol 2020; 38(25): 2839–2848.
159. Horning SJ, Adhikari A, Rizk N, et al. Effect of treatment for Hodgkin’s disease on pulmonary function: results of a prospective study. J Clin Oncol 1994; 12(2): 297–305.
160. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005; 23(30): 7614–7620.
161. Prosnitz LR, Lawson JP, Friedlaender GE, et al. Avascular necrosis of bone in Hodgkin’s disease patients treated with combined modality therapy. Cancer 1981; 47(12): 2793–2797.
Copyright: © 2024 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.